Calian Reports Results for the Second Quarter

In This Article:

Calian Group Ltd.
Calian Group Ltd.

(All amounts in release are in Canadian dollars)

OTTAWA, Ontario, May 14, 2025 (GLOBE NEWSWIRE) -- Calian® Group Ltd. (TSX:CGY), a mission critical solutions company, with a focus on defence, space, healthcare and strategic growth markets, today released its results for the second quarter ended March 31, 2025.

“Our consolidated second quarter results reflect momentum in some areas, whilst challenging headwinds in others,” said Kevin Ford, Calian CEO. “Our defence solutions in both North America and Europe grew by 13%, highlighting the increasing need for global security and operational readiness. Our ITCS business saw a more challenging environment due to slower customer demand, and one-time investments we have made to re-position our offerings for long-term growth.”

Q2-25 Highlights:

  • Revenue at $194 million

  • Gross margin at 33.4%

  • Adjusted EBITDA1 of $17 million

  • Operating free cash flow1 of $10 million

  • Very strong signings of $248 million

  • Growth in our defence end market solutions of 13%

  • Since the launch of the NCIB, the Company repurchased 416,812 shares, or 4% of the float, in consideration of $19.7 million

  • Increasing NCIB - plan to repurchase up to 6% of float in FY25

  • Guidance withdrawn due to ongoing economic and geopolitical uncertainty as well as limited visibility and timing of key opportunities in the ITCS segment

  • Completed the acquisition of Advanced Medical Solutions ("AMS") after quarter end

“Given ongoing economic and geopolitical uncertainty as well as limited visibility and timing of key opportunities in the ITCS segment,  we have made the decision to withdraw our guidance. Despite this, we remain confident in the future growth of Calian given strong momentum in signings, our backlog of close to $1.4 billion, including AMS, optimism around defence spending and a robust M&A pipeline - underscored by our most recent acquisition of AMS.”

 

 

 

 

 

 

 

 

 

 

Financial Highlights

Three months ended

Six months ended

(i(in millions of $, except per share & margins)

March 31,

March 31,

 

2025

 

 

20242

 

%

 

2025

 

 

20242

 

%

Revenue

193.7

 

 

201.3

 

(4)%

 

378.7

 

 

380.4

 

— %

Adjusted EBITDA1

17.4

 

 

27.2

 

(36)%

 

35.2

 

 

48.5

 

(27)%

Adjusted EBITDA %1

9.0

%

 

13.5

%

(450)bps

 

9.3

%

 

12.7

%

(340)bps

Adjusted Net Profit1

11.1

 

 

19.0

 

(42)%

 

21.5

 

 

33.0

 

(35)%

Adjusted EPS Diluted1

0.93

 

 

1.58

 

(41)%

 

1.81

 

 

2.73

 

(34)%

Operating Free Cash Flow1

9.8

 

 

21.0

 

(53)%

 

22.9

 

 

38.2

 

(40)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1 This is a non-GAAP measure. Please refer to the section “Reconciliation of non-GAAP measures to most comparable IFRS measures” at the end of this press release.
2 Certain comparative figures have been reclassified to align with the current year's presentation. For more information, please see the selected consolidated financial information section of the management discussion and analysis.